Luke Sergott
Stock Analyst at Barclays
(2.45)
# 2,383
Out of 5,097 analysts
369
Total ratings
46.74%
Success rate
-0.44%
Average return
Main Sectors:
Stocks Rated by Luke Sergott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TWST Twist Bioscience | Maintains: Overweight | $37 → $39 | $35.06 | +11.24% | 20 | Dec 15, 2025 | |
| RVTY Revvity | Maintains: Overweight | $105 → $115 | $97.77 | +17.62% | 12 | Dec 15, 2025 | |
| QGEN Qiagen | Maintains: Overweight | $53 → $55 | $46.05 | +19.44% | 3 | Dec 15, 2025 | |
| RGEN Repligen | Maintains: Overweight | $175 → $200 | $165.58 | +20.79% | 4 | Dec 15, 2025 | |
| PACB Pacific Biosciences of California | Maintains: Equal-Weight | $1.5 → $2 | $1.82 | +9.89% | 6 | Dec 15, 2025 | |
| NTRA Natera | Maintains: Overweight | $230 → $270 | $235.57 | +14.62% | 6 | Dec 15, 2025 | |
| MTD Mettler-Toledo International | Maintains: Overweight | $1,600 → $1,550 | $1,412.41 | +9.74% | 4 | Dec 15, 2025 | |
| MEDP Medpace Holdings | Maintains: Underweight | $485 → $525 | $571.53 | -8.14% | 5 | Dec 15, 2025 | |
| ILMN Illumina | Maintains: Underweight | $100 → $110 | $137.60 | -20.06% | 22 | Dec 15, 2025 | |
| ICLR ICON Public Limited Company | Maintains: Equal-Weight | $185 → $200 | $179.14 | +11.64% | 23 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $85 → $120 | $101.34 | +18.41% | 6 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $210 → $215 | $203.02 | +5.90% | 11 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $13 | $9.11 | +42.70% | 20 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $55 | $48.77 | +12.77% | 8 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $17 → $22 | $16.94 | +29.87% | 15 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | $10 → $15 | $17.69 | -15.21% | 14 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $165 | $138.52 | +19.12% | 14 | Dec 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $77 → $105 | $101.82 | +3.12% | 9 | Nov 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $20 | $17.28 | +15.74% | 23 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $15 → $12 | $11.24 | +6.76% | 27 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $275 → $325 | $274.89 | +18.23% | 4 | Oct 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $585 → $625 | $575.70 | +8.56% | 29 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $225 → $250 | $228.01 | +9.64% | 41 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $185 → $200 | $224.37 | -10.86% | 24 | Oct 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $90 | $100.71 | -10.63% | 1 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $400 → $350 | $384.14 | -8.89% | 18 | Apr 10, 2025 |
Twist Bioscience
Dec 15, 2025
Maintains: Overweight
Price Target: $37 → $39
Current: $35.06
Upside: +11.24%
Revvity
Dec 15, 2025
Maintains: Overweight
Price Target: $105 → $115
Current: $97.77
Upside: +17.62%
Qiagen
Dec 15, 2025
Maintains: Overweight
Price Target: $53 → $55
Current: $46.05
Upside: +19.44%
Repligen
Dec 15, 2025
Maintains: Overweight
Price Target: $175 → $200
Current: $165.58
Upside: +20.79%
Pacific Biosciences of California
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $1.5 → $2
Current: $1.82
Upside: +9.89%
Natera
Dec 15, 2025
Maintains: Overweight
Price Target: $230 → $270
Current: $235.57
Upside: +14.62%
Mettler-Toledo International
Dec 15, 2025
Maintains: Overweight
Price Target: $1,600 → $1,550
Current: $1,412.41
Upside: +9.74%
Medpace Holdings
Dec 15, 2025
Maintains: Underweight
Price Target: $485 → $525
Current: $571.53
Upside: -8.14%
Illumina
Dec 15, 2025
Maintains: Underweight
Price Target: $100 → $110
Current: $137.60
Upside: -20.06%
ICON Public Limited Company
Dec 15, 2025
Maintains: Equal-Weight
Price Target: $185 → $200
Current: $179.14
Upside: +11.64%
Dec 15, 2025
Maintains: Overweight
Price Target: $85 → $120
Current: $101.34
Upside: +18.41%
Dec 15, 2025
Maintains: Overweight
Price Target: $210 → $215
Current: $203.02
Upside: +5.90%
Dec 15, 2025
Maintains: Overweight
Price Target: $14 → $13
Current: $9.11
Upside: +42.70%
Dec 15, 2025
Maintains: Overweight
Price Target: $45 → $55
Current: $48.77
Upside: +12.77%
Dec 15, 2025
Maintains: Overweight
Price Target: $17 → $22
Current: $16.94
Upside: +29.87%
Dec 15, 2025
Upgrades: Equal-Weight
Price Target: $10 → $15
Current: $17.69
Upside: -15.21%
Dec 15, 2025
Upgrades: Overweight
Price Target: $165
Current: $138.52
Upside: +19.12%
Nov 21, 2025
Downgrades: Equal-Weight
Price Target: $77 → $105
Current: $101.82
Upside: +3.12%
Nov 5, 2025
Maintains: Overweight
Price Target: $19 → $20
Current: $17.28
Upside: +15.74%
Oct 30, 2025
Downgrades: Equal-Weight
Price Target: $15 → $12
Current: $11.24
Upside: +6.76%
Oct 27, 2025
Maintains: Equal-Weight
Price Target: $275 → $325
Current: $274.89
Upside: +18.23%
Oct 23, 2025
Maintains: Overweight
Price Target: $585 → $625
Current: $575.70
Upside: +8.56%
Oct 22, 2025
Maintains: Overweight
Price Target: $225 → $250
Current: $228.01
Upside: +9.64%
Oct 2, 2025
Maintains: Equal-Weight
Price Target: $185 → $200
Current: $224.37
Upside: -10.86%
Aug 1, 2025
Initiates: Overweight
Price Target: $90
Current: $100.71
Upside: -10.63%
Apr 10, 2025
Maintains: Equal-Weight
Price Target: $400 → $350
Current: $384.14
Upside: -8.89%